Skip to main content

Undiagnosed Genetic Disease

Distant relatedness in biobanks harnessed to identify undiagnosed genetic disease


An innovative analysis of shared segments within the genome — an indication of distant “relatedness” — has identified undiagnosed cases of Long QT syndrome, a rare disorder that can lead to abnormal heart rhythms, fainting and sudden cardiac death.

The findings, reported in the journal Nature Communications, illustrate the feasibility of the new approach developed by researchers at Vanderbilt University Medical Center to detect undiagnosed carriers of rare disease-causing genetic variants.

“Rare genetic diseases are usually studied in referral populations — people who have been referred to specialty clinics for evaluation — but this approach often overestimates the true population impact, which would be better assessed in large non-referral populations, such as biobanks,” said Jennifer (Piper) Below, PhD, professor of Medicine in the Division of Genetic Medicine and senior corresponding author of the new study.

Because most biobanks recruit participants from the same region, there is often significant undocumented relatedness among the participants, resulting in genomic segments that are shared due to common ancestry - “identical-by-descent” segments, Below explained.

“Identical-by-descent segments give us an opportunity to cluster related people to find rare variants that were present in a common ancestor,” she said.

To do this, the researchers developed a genetic inference method called DRIVE (Distant Relatedness for Identification and Variant Evaluation). The studies were led by co-first authors Megan Lancaster, MD, PhD, a clinical fellow in the Division of Cardiovascular Medicine, and Hung-Hsin Chen, PhD, who was a postdoctoral fellow in the Division of Genetic Medicine. Dan Roden, MD, the Sam L. Clark, MD, PhD Chair and Senior Vice President for Personalized Medicine, is co-senior author.

To test DRIVE, the researchers focused on a rare variant in the gene KCNE1 that causes Type 5 Long QT syndrome (LQT5). The KCNE1 gene encodes a protein that modifies potassium currents.

An international consortium of 26 centers had identified 89 probands (affected individuals who are the first subjects of a genetic study) with possible LQT5, 140 additional carrier relatives, and 19 cases of another syndrome attributed to variants in KCNE1.

Of 35 probands with the most common KCNE1 variant (p.Asp76Asn), nine (26%) were evaluated by the Genetic Arrhythmia Clinic at VUMC. None of the probands were known to be related. Three relatives of the probands were also found to carry the variant.

“This enrichment of a rare variant at VUMC relative to other centers in the consortium suggested that these local probands may be distantly related and that we could use that relatedness to identify additional carriers in BioVU,” Below said. BioVU is VUMC’s DNA biobank linked to de-identified electronic health records.

The team first estimated the genome-wide relatedness of the 12 clinically identified p.Asp76Asn carriers and constructed lineage pedigrees. They found eighth to ninth degree relatedness among these pedigrees (for reference, fourth cousins — great-grandchildren of first cousins — are ninth degree relatives), supporting the hypothesis of a local common ancestor with the p.Asp76Asn variant.

Then, the researchers identified shared genomic regions that spanned the KCNE1 gene and applied DRIVE to 69,819 BioVU subjects. They identified 22 BioVU subjects with the shared region, confirmed the p.Asp76Asn variant by DNA sequencing, and assessed electrocardiograms and medical records for features of LQT5.

Both referral and non-referral carriers of the variant have prolonged QT interval compared to controls.

“In this study, we used DRIVE to rapidly pinpoint 22 carriers of a previously described pathogenic gene variant,” Below said. “DRIVE could also be used to identify unknown causal gene variants, by clustering individuals with shared identical-by-descent segments and assessing the enrichment of disease within clusters.

“We’re excited about the potential of DRIVE to identify undiagnosed cases of genetic disease.”

Co-first author Chen is now a tenure-track assistant research fellow of the Institute of Biomedical Science at Academia Sinica in Taiwan and holds a joint faculty appointment at VUMC. Other authors of the Nature Communications study include Benjamin Shoemaker, MD, Matthew Fleming, MD, PhD, Teresa Strickland, James Baker, Grahame Evans, Hannah Polikowsky, David Samuels, PhD, and Chad Huff, PhD.

genetics, DNA, gene, chromosome, heredity, mutation, genotype, phenotype, genetic variation, genome, CRISPR, biotechnology, genetic engineering, molecular biology, epigenetics, SNP, genetic disorder, bioinformatics, population genetics, genomics,

#genetics, #DNA, #gene, #chromosome, #heredity, #mutation, #genotype, #phenotype, #geneticvariation, #genome, #CRISPR, #biotechnology, #geneticengineering, #molecularbiology, #epigenetics, #SNP, #geneticdisorder, #bioinformatics, #populationgenetics, #genomics

International Conference on Genetics and Genomics of Diseases 




For Enquiries: genetics@healthcarek.com 

Get Connected Here 
--------------------------------- 
--------------------------------- 

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more